Navigation Links
NeoVista, Inc. Presents New Data on Its Novel Wet AMD Therapy at AAO

One-Year Data Provides Ophthalmologists Critical Insight on Novel Beta

Radiation Epiretinal Therapy

NEW ORLEANS, Nov. 12 /PRNewswire/ -- NeoVista, Inc. revealed today new data from a one-year feasibility study of the company's novel beta radiation epiretinal therapy for the wet form of age-related macular degeneration (AMD) at the 2007 Annual Meeting of the American Academy of Ophthalmology in New Orleans, Louisiana.

NeoVista initiated this study to test the efficacy and safety of their novel beta radiation epiretinal therapy when used in combination with Avastin(R). In the ongoing nonrandomized, multi-center feasibility study, 34 subjects with predominantly classic, minimally classic, or occult (with no classic) CNV received a single 24 Gy treatment of NeoVista's epiretinal therapy in combination with two injections of Avastin, one dose at the time of radiation delivery and another one month later.

After twelve months follow-up, subjects experienced a mean improvement of visual acuity of 13.1 letters using the Early Treatment Diabetic Retinopathy Study (ETDRS) test. 96% of patients lost less than 15 letters of visual acuity. Only 15% of patients in the study required additional injections of Avastin throughout the year and only 12% of patients experienced adverse events related to the procedure (retinal tear, retinal detachment, subretinal hemorrhage, and vitreous hemorrhage).

Jeffrey S. Heier, MD, a retinal specialist and partner at Ophthalmic Consultants of Boston, presented the one-year data attained from 27 trial participants (mean age, 72 years) from June 2006 to April 2007 in two centers in Brazil and one in Mexico. Dr. Heier is a consultant for NeoVista, Inc.

"The one-year data provides important evidence that this novel concomitant treatment approach may provide more sustainable options for those suffering from this degenerative condition," said Dr. Heier. "NeoVista's targeted beta radiation in this study demonstrated its differences from previous attempts by the medical community to use radiation for the treatment of wet AMD. Additional on-going studies may well confirm the viability of this new therapeutic option for the elderly with wet AMD."

Unlike previous forms of radiation therapy for Wet AMD, NeoVista's approach delivers the peak dose of radiation directly to the lesion without damaging the underlying choroidal vasculature. Utilizing strontium-90, the focused radiation is delivered to a target area 3 mm in depth and up to 5.4 mm in diameter. Importantly for patients, the systemic exposure to radiation is minimal, as the effective dose to the entire body from NeoVista's epiretinal device is comparable to 15 minutes of exposure to the sun.

"The ultimate promise of this therapy revolves around that fact that NeoVista's targeted radiation delivery system allows patients to continue living their lives, with significantly less injections, while also having the potential to save both patients and the healthcare system billions of dollars," said John N. Hendrick, President and CEO of NeoVista. "We look forward to unveiling the true impact of our therapy on patients and physicians now that our larger CABERNET trial is underway."

The CABERNET (CNV Secondary to AMD Treated with BEta RadiatioN Epiretinal Therapy) trial is a multi-center, randomized, controlled study which will enroll 450 subjects at 30 sites worldwide (20 in the United States). The study will evaluate the safety and efficacy of NeoVista's beta radiation epiretinal therapy delivered concomitantly with the FDA approved antiangiogenic therapy, Lucentis(R), versus Lucentis(R) alone.

About NeoVista, Inc.

NeoVista, Inc. is a privately held development-stage medical device company based in Fremont, California. NeoVista's beta radiation epiretinal therapy is currently being studied in a definitive clinical study to support eventual filing for regulatory approval to market the product in the United States. For more information about the company, the clinical trial or this novel wet AMD therapy, please visit the company's Web site at

SOURCE NeoVista, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Post Your Comments:
(Date:11/26/2015)... Research and Markets ( ) has announced ... Outlook to 2019 - Rise in Cardiac Disorders and Growing ... to their offering. Boston ... scientific and others. --> The market ... Boston scientific and others. ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... of the "2016 Future Horizons and Growth ... Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> --> ... of the Japanese therapeutic drug monitoring market, including ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the Global Cell Surface Testing ... Opportunities" report to their offering.  ... the addition of the  "2016 Future ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... The successful filing of an Investigational ... it is so important to this key industry segment, Regis Technologies has decided to ... on December 4th at 11am EST. , Federal law does not allow new drugs ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... of critical importance to the medical schools of the future. To reach an ... suite at the 2015 ChangeMedEd conference in Chicago, organized by the American Medical ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... their strategic partnership at the Radiological Society of North America (RSNA) 2015 ... global providers of cutting-edge dictation and speech-enabled documentation software, announced their partnership ...
(Date:11/30/2015)... Wylie, TX (PRWEB) , ... November 30, 2015 , ... Bayco Products, Inc today announced ... only $11.95 each. Available in a choice of three different colors; red ( NSP-1632 ), ... can each run up to 18 hours in constant-on mode, or 27 hours in blinking ...
(Date:11/29/2015)... FL (PRWEB) , ... November 30, 2015 , ... The Cyber Monday deal is a ... It is the right time to get gifts for the skin care lover in your ... top filled with serums . This year, the 3 serums are staples: Collagen, Retinol and ...
Breaking Medicine News(10 mins):